MARKET

FOLD

FOLD

Amicus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.68
+0.06
+0.41%
After Hours: 14.68 0 0.00% 16:16 08/13 EDT
OPEN
14.63
PREV CLOSE
14.62
HIGH
14.85
LOW
14.33
VOLUME
2.86M
TURNOVER
--
52 WEEK HIGH
16.13
52 WEEK LOW
6.25
MARKET CAP
3.80B
P/E (TTM)
-12.8310
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FOLD stock price target is 19.50 with a high estimate of 31.00 and a low estimate of 12.00.

EPS

FOLD News

More
Citigroup Maintains Buy on Amicus Therapeutics, Raises Price Target to $20
Citigroup maintains Amicus Therapeutics (NASDAQ:FOLD) with a Buy and raises the price target from $15 to $20.
Benzinga · 2d ago
Amicus Therapeutics Inc (FOLD) Q2 2020 Earnings Call Transcript
Thank you for joining our conference call to discuss Amicus Therapeutics' second quarter 2020 financial results and corporate highlights. Speaking on today's call, we have John Crowley, Chairman and Chief Executive Officer; Bradley Campbell, President and Chi
Motley Fool · 3d ago
Amicus Therapeutics Affirms FY2020 Sales Guidance from $250.00M-260.00M to $250.00M-260.00M
Amicus Therapeutics (NASDAQ:FOLD) affirms FY2020 sales outlook from $250.00 million-260.00 million to $250.00 million-260.00 million.
Benzinga · 3d ago
Amicus Therapeutics (FOLD) Reports Q2 Loss, Misses Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 23.08% and -0.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
Recap: Amicus Therapeutics Q2 Earnings
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 44.44% year over year to ($0.20), which beat the estimate of ($0.26).Revenue of $62,353,000 rose by
Benzinga · 3d ago
Amicus Therapeutics Q2 EPS $(0.20) Beats $(0.26) Estimate, Sales $62.35M Miss $62.38M Estimate
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.26) by 23.08 percent. This is a 44.44 percent increase over losses of $(0.36) per share
Benzinga · 3d ago
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
Galafold 2Q2020 Revenue of $62.4 Million, On-Track to Achieve 2020 Revenue Guidance of  $250M-$260MAT-GAA Phase 3 PROPEL Study Readout and Rolling BLA Submission to U.S. FDA on ScheduleAdvancing Industry-Leading Rare Disease Gene Therapy PortfolioPath to Prof
GlobeNewswire · 3d ago
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020
GlobeNewswire · 08/04 11:00

Industry

Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
-0.06%

Hot Stocks

Symbol
Price
%Change

About FOLD

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The Company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
More

Webull offers kinds of Amicus Therapeutics, Inc. stock information, including NASDAQ:FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.